This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

High-Tech Advances In Gene Therapy Overcome Challenges, Offer Hope For Patients With Hard-to-Treat Blood Disorders

Other advances in cell engineering reported today include a new generation of gene "vector" therapy that self-destructs once it delivers critical, missing genetic material to a patient, solving the issue of T cell overgrowth observed in previous studies. Finally, genetic modifications of haploidentical (or half-matched) stem cells prior to transplant could expand the utility of this treatment approach to a much wider range of patients in the coming years by reducing the risk of transplant infections. 

"It's exciting to see these encouraging initial results with engineered immune cells, particularly such a durable response among patients who have very aggressive disease that has relapsed after standard treatments," said Laurence Cooper, MD, of The University of Texas MD Anderson Cancer Center in Houston. "With the right technology and laboratory expertise, the process of cell engineering is feasible for many patients. One remaining challenge is determining why some patients benefit and others have less durable responses. Does 'one size fits all' therapy work or do we need personalized or individualized T cell treatments? Further, we need to extend these studies to other tumor types, particularly solid tumors, to evaluate their potential in other clinical settings."

This press conference will take place on Saturday, December 7, 2013 at 8:00 a.m. CST.

Removal of Alpha/Beta+ T Cells and of CD19+ B Cells From the Graft Translates Into Rapid Engraftment, Absence of Visceral Graft-Versus-Host Disease and Low Transplant-Related Mortality in Children With Acute Leukemia Given HLA-Haploidentical Hematopoietic Stem Cell Transplantation [ 157 ]

Transplants of haploidentical, or half-matched, blood-forming stem cells may be an effective option for patients in need of a transplant without a fully matched donor; however, in the past, in comparison to transplant from a fully matched donor, this treatment has been associated with an increased risk of infection and disease recurrence. This study tested the effectiveness of manipulating in the lab these half-matched donor stem cells. 

2 of 6

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs